Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation
- PMID: 10338054
- DOI: 10.1038/sj.bmt.1701732
Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation
Abstract
A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical